The Sosa laboratory is focused on the different diseases of the thyroid, parathyroid, pancreas and adrenal glands.
Although the primary focus is health services research and health outcomes, other areas of interest include examining different issues along the continuum of patient care, including translational research, the psychological and economic impact on patients of endocrine diseases and their subsequent treatment, and patients’ decisions regarding the different diagnostic and treatment strategies available to them.
In conjunction with several collaborators at Duke, UNC and Yale, among others, the Sosa lab is involved in the development of novel drugs for advanced and unresectable thyroid cancer, cancer genomics, new technologies for the study of single cell physiology, point of care biochemical evaluations, and stem cell therapy for hypoparathyroidism.
Our research is focused on the different diseases of the thyroid, parathyroid, pancreas, and adrenal glands. Although our primary focus is health services research and health outcomes, we are also interested in examining different issues along the continuum of patient care, including translational research, clinical trials for novel therapies and patient repored outcomes, among others.
Research Programs and Centers
Tissue and Serum Acquisition Protocol for Molecular Analysis and Cell Culture in Patients Undergoing Parathyroid Surgery
The state of knowledge in this field is very limited, and investigators are faced with developing a basic understanding of potential relationships between several thousand or tens of thousands of genes and their associations with outcomes. Acquisition of parathyroid tissue and serum specimens at the time of definitive surgery for parathyroid disease is a crucial prerequisite for present and future laboratory and translational scientific programs.
Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules
Targeted next generation sequencing (NGS) platforms allow testing for tens and hundreds mutational hotspots. Additional mutational mutations in thyroid cancer have been identified, and promising markers associated with tumor prognosis have been found. By participating in this multi-institutional study, we hope to assist in the validation of these markers.
Funding: University of Pittsburgh
Thyroid Cancer and Polybrominated Diphenyl Ether (PBDE) Exposure
Excessive environmental exposure of adult patients to PBDE chemicals is associated with the development of papillary thyroid carcinoma, and may account for the increasing incidence of thyroid cancer in the United States. Clinical-translational mechanisms are used to explore the association between PBDE exposure, serum PBDE levels, and thyroid cancer.
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
The study examines the response of tumors following treatment with radioactive iodine in combination with placebo or selumetinib for RAIA recurrent and/or metastatic thyroid cancer.
Funding: Academic and Community Cancer Research United
RIFTOS MKI – An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
This is an international prospective, open-label, multi-center, non-interventional study designed to compare treatment options in DTC. Practice patterns of care of patients with RAI-refractory DTC under real-life conditions will be evaluated.
Funding: Bayer Healthcare
Eisai – An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
The study will evaluate the effectiveness and safety of lenvatinib, also known as LENVIMA™, (approved by the FDA February 13, 2015 in the U.S.) in patients with anaplastic thyroid cancer (ATC). Lenvatinib may offer a new treatment option that will be more effective than the standard drugs used for ATC by stopping the formation of new blood vessels that help cancer cells grow and spread. Lenvatinib is taken by mouth in capsule form and is to taken on a daily basis. Lenvatinib is a drug that was approved by the FDA (the U.S. Food and Drug Administration) on February 13, 2015 in the U.S. Funding: Eisai, Inc.
Goffredo, P, Robinson, TJ, Youngwirth, LM, Roman, SA, and Sosa, JA. "Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes." Endocrine 53, no. 3 (September 2016): 761-773. PMID: 27025947
Anderson, KL, Youngwirth, LM, Scheri, RP, Stang, MT, Roman, SA, and Sosa, JA. "T1a Versus T1b Differentiated Thyroid Cancers: Do We Need to Make the Distinction?." Thyroid: official journal of the American Thyroid Association 26, no. 8 (August 2016): 1046-1052. PMID: 27266722
Pontius, LN, Youngwirth, LM, Thomas, SM, Scheri, RP, Roman, SA, and Sosa, JA. "Lymphovascular invasion is associated with survival for papillary thyroid cancer." Endocrine-Related Cancer 23, no. 7 (July 2016): 555-562. PMID: 27317633
Jillard, CL, Youngwirth, L, Scheri, RP, Roman, S, and Sosa, JA. "Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma." Thyroid: official journal of the American Thyroid Association 26, no. 7 (July 2016): 959-964. PMID: 27150319
Ruel, E, Thomas, S, Dinan, MA, Perkins, JM, Roman, SA, and Sosa, JA. "Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer." Endocrine 52, no. 3 (June 2016): 579-586. PMID: 26708045
Adam, MA, Thomas, S, Youngwirth, L, Hyslop, T, Reed, SD, Scheri, RP, Roman, SA, and Sosa, JA. "Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?" Annals of Surgery (March 8, 2016). PMID: 26967630
Youngwirth, LM, Adam, MA, Scheri, RP, Roman, SA, and Sosa, JA. "Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer." Annals of Surgical Oncology 23, no. 2 (February 2016): 403-409. PMID: 26416710
Adam, MA, Goffredo, P, Youngwirth, L, Scheri, RP, Roman, SA, and Sosa, JA. "Same thyroid cancer, different national practice guidelines: When discordant American Thyroid Association and National Comprehensive Cancer Network surgery recommendations are associated with compromised patient outcome." Surgery 159, no. 1 (January 2016): 41-50. PMID: 26435426
Englum, BR, Pura, J, Reed, SD, Roman, SA, Sosa, JA, and Scheri, RP. "A Bedside Risk Calculator to Preoperatively Distinguish Follicular Thyroid Carcinoma from Follicular Variant of Papillary Thyroid Carcinoma." World Journal of Surgery 39, no. 12 (December 2015): 2928-2934. PMID 26324158
Goffredo, P, Thomas, SM, Adam, MA, Sosa, JA, and Roman, SA. "Impact of Timeliness of Resection and Thyroidectomy Margin Status on Survival for Patients with Anaplastic Thyroid Cancer: An Analysis of 335 Cases." Annals of Surgical Oncology 22, no. 13 (December 2015): 4166-4174. PMID: 26271394
Adam, MA, Pura, J, Goffredo, P, Dinan, MA, Reed, SD, Scheri, RP, Hyslop, T, Roman, SA, and Sosa, JA. "Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer." Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 33, no. 21 (July 2015): 2370-2375. PMID: 26077238
Goffredo, P, Thomas, SM, Dinan, MA, Perkins, JM, Roman, SA, and Sosa, JA. "Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse." JAMA Internal Medicine 175, no. 4 (April 2015): 638-640. PMID: 25686394
Adam, MA, Pura, J, Goffredo, P, Dinan, MA, Hyslop, T, Reed, SD, Scheri, RP, Roman, SA, and Sosa, JA. "Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years." The Journal of Clinical Endocrinology and Metabolism 100, no. 1 (January 2015): 115-121. PMID: 25337927
Adam, MA, Speicher, P, Pura, J, Dinan, MA, Reed, SD, Roman, SA, and Sosa, JA. "Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes." Annals of Surgical Oncology 21, no. 12 (November 2014): 3859-3864. PMID: 24934584
Adam, MA, Pura, J, Gu, L, Dinan, MA, Tyler, DS, Reed, SD, Scheri, R, Roman, SA, and Sosa, JA. "Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients." Annals of Surgery 260, no. 4 (October 2014): 601-605. PMID: 25203876
Wang, TS, Goffredo, P, Sosa, JA, and Roman, SA. "Papillary thyroid microcarcinoma: an over-treated malignancy?" World Journal of Surgery 38, no. 9 (September 2014): 2297-2303. PMID: 24791670
Goffredo, P, Roman, SA, and Sosa, JA. "Have 2006 ATA practice guidelines affected the treatment of differentiated thyroid cancer in the United States?." Thyroid: official journal of the American Thyroid Association 24, no. 3 (March 2014): 463-471. PMID: 23978295
Sosa, JA, Hanna, JW, Robinson, KA, and Lanman, RB. "Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States." Surgery 154, no. 6 (December 2013): 1420-1426. PMID: 24094448
Nussbaum, DP, Adam, MA, Youngwirth, LM, Ganapathi, AM, Roman, SA, Tyler, DS, Sosa, JA, and III, BDG. "Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma." Annals of Surgical Oncology 23, no. 3 (March 2016): 1026-1033. PMID: 26542590
Adam, MA, Choudhury, K, Goffredo, P, Reed, SD, Blazer, D, Roman, SA, and Sosa, JA. "Minimally Invasive Distal Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1,733 Patients." World Journal of Surgery 39, no. 10 (October 2015): 2564-2572. PMID: 26154576
Adam, MA, Choudhury, K, Dinan, MA, Reed, SD, Scheri, RP, Blazer, DG, Roman, SA, and Sosa, JA. "Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients." Annals of Surgery 262, no. 2 (August 2015): 372-377. PMID: 26158612
Gratian, L, Pura, J, Dinan, M, Roman, S, Reed, S, and Sosa, JA. "Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States." Annals of Surgical Oncology 21, no. 11 (October 2014): 3515-3521. PMID: 24841347
Gratian, L, Pura, J, Dinan, M, Reed, S, Scheri, R, Roman, S, and Sosa, JA. "Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States." Annals of Surgical Oncology 21, no. 11 (October 2014): 3509-3514. PMID: 25069860
Kazaure, HS, Roman, SA, Tyler, D, and Sosa, JA. "The significance of atrial fibrillation in patients aged ≥ 55 years undergoing abdominal surgery." World Journal of Surgery 39, no. 1 (January 2015): 113-120. PMID: 25223740
Kazaure, HS, Roman, SA, and Sosa, JA. "A population-level analysis of 5620 recipients of multiple in-hospital cardiopulmonary resuscitation attempts." Journal of Hospital Medicine 9, no. 1 (January 1, 2014): 29-34. PMID: 24311461
Chen, MM, Yeo, HL, Roman, SA, Bell, RH, and Sosa, JA. "Life events during surgical residency have different effects on women and men over time." Surgery 154, no. 2 (August 2013): 162-170. PMID: 23889946
Kazaure, HS, Roman, SA, Rosenthal, RA, and Sosa, JA. "Cardiac arrest among surgical patients: an analysis of incidence, patient characteristics, and outcomes in ACS-NSQIP." JAMA Surgery 148, no. 1 (January 2013): 14-21. PMID: 23324834
To make an appointment, please call 888.275.3853. For more information on endocrine system cancer care at Duke Health, visit:
Age Should Not Drive Thyroid Cancer Staging
A study from the Duke Cancer Institute finds a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More